US Government Awards $481M To Help Cue Health Expand COVID-19 Test Production
Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.
You may also be interested in...
After federal agencies invested almost $500m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. It's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
After the US government invested almost half a billion dollars to ensure Cue Health could scale up production, the FDA announced the self-administered test will now be available over the counter.
Tests will be priced at under $5 each for low- and middle-income countries.